This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.

Phase 4 Not yet recruiting 120 enrolled University of British Columbia Boehringer Ingelheim · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a trial designed to evaluate the combination of nerandomilast with mycophenolate across a wide variety of pulmonary fibrosis subtypes, with the aim of providing clinicians with assurance that this is an appropriate therapeutic combination.

Timeline

Start: 2026-06
Primary completion: 2027-06
Completion: 2027-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nerandomilast	Small molecule	18 mg	—

This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.

Summary

Timeline

Drugs

Indications